

Name of Journal: *World Journal of Gastrointestinal Oncology*

Manuscript NO: 65145

Manuscript Type: MINIREVIEWS

Immune aspects of hepatocellular carcinoma: From immune markers for early detection to immunotherapy

Immune aspects of hepatocellular carcinoma

Abstract

Hepatocellular carcinoma is among the most prevalent cancers and among the main causes of cancer-related deaths worldwide. Most hepatocellular carcinomas develop in an inflammatory microenvironment, and mounting evidence emphasizes the importance of immune aspects in hepatocarcinogenesis. In normal physiology both innate and adaptive immune responses are responsible for eliminating malignantly transformed cells, thus preventing the development of liver cancer. However, in the

Match Overview

1	Crossref 124 words José Debes, Pablo Romagnoli, Jhon Prieto, Marco Arrese ... Angelo Mattos, André Boonstra. "Serum Biomarkers for the	3%
2	Internet 32 words crawled on 16-May-2021 www.frontiersin.org	1%
3	Crossref 31 words Ângelo Zambam de Mattos, Jose D Debes, Andre Boonstr a, Ju-Dong Yang et al. "Current impact of viral hepatitis or ...	1%
4	Internet 24 words crawled on 15-Jul-2020 link.springer.com	1%
5	Crossref 21 words Ryungsa Kim. "Potential functional role of plasmacytoid den dritic cells in cancer immunity", Immunology, 6/2007	<1%
6	Internet 21 words crawled on 07-Feb-2021 www.longdom.org	<1%
7	Internet 20 words crawled on 19-Jun-2017 orca.cf.ac.uk	<1%
8	Internet 20 words crawled on 28-Dec-2020	<1%

ALL

IMAGES

VIDEOS

221,000 Results

Any time ▾

Hepatocellular Carcinoma from an Immunologic Perspective ...

<https://clincancerres.aacrjournals.org/content/19/24/6678> ▾

Dec 15, 2013 · Glypican-3 (GPC3) has emerged as an interesting target for immunotherapy in hepatocellular carcinoma. GPC3 is a member of the glypican family of heparan sulfate proteoglycans that are attached to the cell surface. GPC3 is specifically overexpressed in approximately 80% of hepatocellular carcinoma, and correlates with poor prognosis . Different studies suggest that it may be ...

Cited by: 98

Author: Tim F. Greten, Austin G. Duffy, Firouzeh Kor...

Publish Year: 2013

Estimated Reading Time: 12 mins

Immunotherapy for Hepatocellular Carcinoma: A 2021 Update

<https://pubmed.ncbi.nlm.nih.gov/33020428>

Hepatocellular carcinoma (HCC) is one of one of the most frequent liver cancers and the fourth leading cause of **cancer**-related mortality worldwide. Current treatment options such as surgery, neoadjuvant chemoradiotherapy, liver transplantation, and radiofrequency ablation will benefit only a very small percentage of patients.

Cited by: 9

Author: Christo Kole, Nikolaos Charalampakis, Serg...

Publish Year: 2020

PEOPLE ALSO ASK

Are there any immune responses to hepatocellular carcinoma? ▾

Can a checkpoint inhibitor be used to treat hepatocellular carcinoma? ▾

227,000 Results

Any time ▾

Immunotherapy for Hepatocellular Carcinoma: A 2021 Update

<https://pubmed.ncbi.nlm.nih.gov/33020428>

Hepatocellular carcinoma (HCC) is one of one of the most frequent liver cancers and the fourth leading cause of **cancer**-related mortality worldwide. Current treatment options such as surgery, neoadjuvant chemoradiotherapy, liver transplantation, and radiofrequency ablation will benefit only a very small percentage of patients.

Cited by: 12

Author: Christo Kole, Nikolaos Charalampakis, Serg...

Publish Year: 2020

Hepatocellular Carcinoma from an Immunologic Perspective ...

<https://clincancerres.aacrjournals.org/content/19/24/6678> ▾

Dec 15, 2013 · **Immunotherapy** in **hepatocellular carcinoma**. **Immunotherapy** has been tested in **hepatocellular carcinoma** for many years. Most studies in the past have either used cytokine or antigen-based approaches . Although most of these studies have proven to be safe and able to induce tumor-specific immune responses, most of them have failed to demonstrate clinical efficacy.

Cited by: 97

Author: Tim F. Greten, Austin G. Duffy, Firouzeh Kor...

Publish Year: 2013

Estimated Reading Time: 12 mins

PEOPLE ALSO ASK

Are there markers for hepatocellular carcinoma (HCC)? ▾

Are there any immune responses to hepatocellular carcinoma? ▾

Is there a systemic treatment for advanced hepatocellular carcinoma (HCC)? ▾

Where can I get immunotherapy for hepatocellular carcinoma? ▾

Feedback

Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes

<https://pubmed.ncbi.nlm.nih.gov/29138342>

Treatment of patients with **hepatocellular carcinoma** (HCC) in the advanced stage remains a great challenge, with very few drugs approved. After decades of failure of **immune** therapies, **immune**

Hepatocellular Carcinoma


Medical Condition

The most common form of liver cancer often seen in people with chronic liver diseases like cirrhosis.

 Rare (Fewer than 200,000 cases per year in US)

 May be preventable by vaccine

 Often requires lab test or imaging

 Treatable by a medical professional

 Can last several months or years

It is caused mainly due to the chronic infection of the liver or DNA mutation of the liver cells. It is characterized by unexplained weight loss, upper abdominal pain and yellowing of the skin. Treatment options include hepatectomy, target drug delivery and the use of radiation to kill the cancerous cells.

Symptoms

The early stages of the disease do not present any symptoms but in the later stages the symptoms which are noted are as follows:

- Upper abdominal pain
- Weight loss
- Jaundice
- Fluid in the abdomen
- Liver failure

Treatments

Treatment options include hepatectomy, target drug delivery and the use of radiation to kill the cancerous cells.

Medication

- Chemotherapy: Therapy where the drugs are used to kill the cancer cells.
5-Fluorouracil · Capecitabine · Irinotecan · Oxaliplatin